Stryker Corporation
Every calculator, already run for SYK
Open the full toolkit →You have the numbers on SYK. Get the argument.
A written report on which of these readings actually decide the outcome for Stryker Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
28 analysts covering SYKAnalyst Price Target Disagreement for Stryker Corporation
Wall Street's bull case implies +69% from the current price; the bear case implies +8%. A 61% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for SYK
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Stryker Corporation
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical…
SYK — frequently asked
Is SYK a buy right now?
Wall Street's consensus rating on Stryker Corporation is Buy across 28 analysts, with a mean price target of $369.00 (+34% vs. the current $275.09). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is SYK overvalued?
SYK trades at 28.5x trailing earnings, against a DCF fair value of $282 per share. The current price implies 6% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is SYK's next earnings date?
Stryker Corporation is next scheduled to report earnings around Oct 29, 2026. A full SYK research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Stryker Corporation?
Analysts covering Stryker Corporation (SYK) range from a bear-case target of $298.00 to a bull-case high of $465.00, with a mean consensus target of $369.00 across 25 analysts. The spread of $167.00 (61% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Stryker Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Stryker Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full SYK research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Stryker Corporation, in minutes. 3 free reports included with every account — no credit card required.